Abeona Therapeutics (ABEO) Expected to Announce Earnings on Monday

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) is expected to release its earnings data before the market opens on Monday, March 17th. Analysts expect Abeona Therapeutics to post earnings of ($0.35) per share and revenue of $0.10 million for the quarter.

Abeona Therapeutics Trading Down 5.4 %

ABEO stock traded down $0.30 during midday trading on Thursday, reaching $5.29. The stock had a trading volume of 230,789 shares, compared to its average volume of 307,701. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $8.87. The firm has a market cap of $229.96 million, a price-to-earnings ratio of -1.96 and a beta of 1.79. The business has a fifty day simple moving average of $5.54 and a two-hundred day simple moving average of $5.85.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. StockNews.com cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 22nd. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. Finally, Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.50.

Remove Ads

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.